A Study of Fianlimab and Cemiplimab for Head and Neck Cancer
This study is looking at whether combining two medications, fianlimab and cemiplimab, works better than cemiplimab alone for people with head and neck squamous cell carcinoma (HNSCC) that has returned or spread (recurrent or metastatic). You might be able to join if you are 18 or older and have HNSCC that started in your mouth, throat, or voice box, and has not been treated before for its recurrence or spread. Researchers will measure how many participants respond to the treatment to see if the combination is effective. The study aims to enroll 120 participants.
- Study design
- This interventional study plans to enroll 120 participants. It compares fianlimab plus cemiplimab against cemiplimab plus a placebo (an inactive substance that looks like medicine).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 90 days after their last study treatment, for approximately 58 months in total.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
At a glance
Conditions
Where it's being run
35 sites across 26 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall Response Rate (ORR)Up to 90 days after last study treatment, approximately 58 months